APOE4 induces site-specific tau phosphorylation through calpain-CDK5 signaling pathway in EFAD-Tg mice

Current Alzheimer Research

Volumn 13, Issue 9, 2016, Pages 1048-1055

  Zhou, Meng ^a   Huang, Tianwen ^a   Collins, Nicole ^b   Zhang, Jing ^a   Shen, Hui ^a   Dai, Xiaoman ^a   Xiao, Naian ^a   Wu, Xilin ^a   Wei, Zhen ^a   York, Jason ^b   Lin, Lanyan ^a   Zhu, Yuangui ^a   LaDu, Mary Jo ^b   Chen, Xiaochun ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alzheimer s disease; Amyloid beta; Apolipoprotein E; Calpain CDK5; EFAD mice; Phosphorylation; Tau

Indexed keywords

APOLIPOPROTEIN E4; CALPAIN; CALPAIN 1; CALPAIN 2; CYCLIN DEPENDENT KINASE 5; PROTEIN P25; PROTEIN P35; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CDK5 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3BETA; MAPT PROTEIN, MOUSE; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; AGING; ANIMAL; BRAIN CORTEX; GENETICS; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

AGING; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E4; CALPAIN; CEREBRAL CORTEX; CYCLIN-DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MALE; MICE, TRANSGENIC; MUTATION; NEURONS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84981523355     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160415154550     Document Type: Article

References (82)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8(6): 429-31 (1995).
2. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 114(1-2): 107-13 (2001).
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr., Rimmler JB, et al. Apolipoprotein E, survival in Alzheimer’s disease patients, and the competing risks of death and Alzheimer’s disease. Neurology 45(7): 1323-8 (1995).
4. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer’s disease. Ann Neurol 38(1): 6-14 (1995).
5. Kim D, Tsai LH. Bridging physiology and pathology in AD. Cell 137(6): 997-1000 (2009).
6. Leduc V, Jasmin-Belanger S, Poirier J. APOE and cholesterol homeostasis in Alzheimer’s disease. Trends Mol Med 16(10): 469-77 (2010).
7. Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, et al. Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135(Pt 7): 2155-68 (2012).
8. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123): 921-3 (1993).
9. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43(8): 1467-72 (1993).
10. Houlden H, Crook R, Backhovens H, Prihar G, Baker M, Hutton M, et al. ApoE genotype is a risk factor in nonpresenilin earlyonset Alzheimer’s disease families. Am J Med Genet 81: 117-21 (1998).
11. Breitner JC, Jarvik GP, Plassman BL, Saunders AM, Welsh KA. Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Dis Assoc Disord 12(1): 40-4 (1998).
12. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16): 1349-56 (1997).
13. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 61(5): 518-24 (2004).
14. Takeda M, Martinez R, Kudo T, Tanaka T, Okochi M, Tagami S, et al. Apolipoprotein E and central nervous system disorders: Reviews of clinical findings. Psychiatr Clin Neurosci 64(6): 592-607 (2010).
15. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol 10(3): 241-52 (2011).
16. Bu G. Apolipoprotein E and its receptors in Alzheimer’s disease: Pathways, pathogenesis and therapy. Nat Rev Neurosci 10(5): 333-44 (2009).
17. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240(4852): 622-30 (1988).
18. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron 63(3): 287-303 (2009).
19. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci 32(43): 15181-92 (2012).
20. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem 287(50): 41774-86 (2012).
21. Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem 288(8): 5914-26 (2013).
22. Tai LM, Mehra S, Shete V, Estus S, Rebeck GW, Bu G, et al. Soluble apoE/Abeta complex: Mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener 9(1): 2 (2014).
23. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol 41(6): 1261-8 (2009).
24. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res 541: 163-66 (1991).
25. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90(5): 1977-81 (1993).
26. Genis I, Gordon I, Sehayek E, Michaelson DM. Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci Lett 199(1): 5-8 (1995).
27. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24(10): 2527-34 (2004).
28. Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: Modulation by zinc. J Biol Chem 279(43): 44795-801 (2004).
29. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 156(3): 951-64 (2000).
30. Liraz O, Boehm-Cagan A, Michaelson DM. ApoE4 induces Abeta42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol Neurodegener 8: 16 (2013).
31. Kobayashi M, Ishiguro K, Katoh-Fukui Y, Yokoyama M, Fujita SC. Phosphorylation state of tau in the hippocampus of apolipoprotein E4 and E3 knock-in mice. Neuroreport 14(5): 699-702 (2003).
32. Inbar D, Belinson H, Rosenman H, Michaelson DM. Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade. Neurodegener Dis 7(1-3): 16-23 (2010).
33. Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, Wu S, et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 32(5): 791-801 (2011).
34. Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28(45): 11445-53 (2008).
35. Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW. Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. J Neuroinflamm 11(1): 111 (2014).
36. Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, et al. APOE-modulated Abeta-induced neuroinflammation in Alzheimer’s disease: Current landscape, novel data and future perspective. J Neurochem 133(4): 465-88 (2015).
37. Cacciottolo M, Christensen A, Moser A, Liu J, Pike CJ, Smith C, et al. The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer’s disease of humans and mice. Neurobiol Aging 37: 47-57 (2016).
38. Liu DS, Pan XD, Zhang J, Shen H, Collins NC, Cole AM, et al. APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener 10(1): 7 (2015).
39. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Finch CE. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: Implications for Alzheimer’s disease. J Neurosci 18(9): 3180-5 (1998).
40. Wallace M, Luine V, Arellanos A, Frankfurt M. Ovariectomized rats show decreased recognition memory and spine density in the hippocampus and prefrontal cortex. Brain Res 1126(1): 176-82 (2006).
41. Phan A, Gabor CS, Favaro KJ, Kaschack S, Armstrong JN, MacLusky NJ, et al. Low doses of 17beta-estradiol rapidly improve learning and increase hippocampal dendritic spines. Neuropsychopharmacology 37(10): 2299-309 (2012).
42. Schuenke K, Gelman BB. Human microglial cell isolation from adult autopsy brain: Brain pH, regional variation, and infection with human immunodeficiency virus type 1. J Neurovirol 9(3): 346-57 (2003).
43. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9(1): 63-75 e2 (2013).
44. Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging 30(9): 1350-60 (2009).
45. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1): a006189 (2011).
46. Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Grant P, et al. A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer’s disease phenotypes in model mice. FASEB J 27(1): 174-86 (2013).
47. Apetz N, Munch G, Govindaraghavan S, Gyengesi E. Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer’s disease--a translational perspective. CNS Neurol Disord Drug Targets 13(7): 1175-91 (2014).
48. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42(3 Pt 1): 631-9. (1992).
49. Lee WH, Loo CY, Bebawy M, Luk F, Mason RS, Rohanizadeh R. Curcumin and its derivatives: Their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol 11(4): 338-78 (2013).
50. Bastianetto S, Menard C, Quirion R. Neuroprotective action of resveratrol. Biochim Biophys Acta 1852(6): 1195-201 (2015).
51. Li SY, Wang XB, Kong LY. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer’s disease. Eur J Med Chem 71: 36-45 (2014).
52. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 278(49): 48529-33 (2003).
53. Warpeha KM, Gibbons J, Carol A, Slusser J, Tree R, Durham W, et al. Adequate phenylalanine synthesis mediated by G protein is critical for protection from UV radiation damage in young etiolated Arabidopsis thaliana seedlings. Plant Cell Environ 31(12): 1756-70 (2008).
54. Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L. Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochim Biophys Acta 1852(6): 1202-08 (2015).
55. Halliwell B. Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence? Lancet 344(8924): 721-4 (1994).
56. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 70(19 Pt 2): 1842-9 (2008).
57. Ikeda M, Tashiro Y, Takai E, Kurose S, Fugami N, Tsuda K, et al. CSF levels of Abeta1-38/Abeta1-40/Abeta1-42 and (11)C PiB-PET studies in three clinical variants of primary progressive aphasia and Alzheimer’s disease. Amyloid 21(4): 238-45 (2014).
58. Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM. CSF biomarkers in Alzheimer’s disease and controls: Associations with APOE genotype are modified by age. J Alzheimers Dis 16(3): 601-7 (2009).
59. Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, Bernardo A, Yoon SY, et al. Apolipoprotein E4 causes age-and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci 30(41): 13707-17 (2010).
60. Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, et al. Apolipoprotein E and cognitive performance. Nature 404(6776): 352-4 (2000).
61. Obulesu M, Rao DM. Effect of plant extracts on Alzheimer’s disease: An insight into therapeutic avenues. J Neurosci Rural Pract 2(1): 56-61 (2011).
62. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11(3): 332-84 (2015).
63. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402(6762): 615-22 (1999).
64. Perl DP. Neuropathology of Alzheimer’s disease. Mt Sinai J Med 77(1): 32-42 (2010).
65. Hayden EY, Teplow DB. Amyloid beta-protein oligomers and Alzheimer’s disease. Alzheimers Res Ther 5(6): 60 (2013).
66. Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: A systematic review and meta-analysis. Neuroepidemiology 38(1): 1-17 (2012).
67. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9(2): 106-18 (2013).
68. Fraga CG, Martino VS, Ferraro GE, Coussio JD, Boveris A. Flavonoids as antioxidants evaluated by in vitro and in situ liver chemiluminescence. Biochem Pharmacol 36(5): 717-20 (1987).
69. Ratty AK, Das NP. Effects of flavonoids on nonenzymatic lipid peroxidation: Structure-activity relationship. Biochem Med Metab Biol 39(1): 69-79 (1988).
70. Cole GM, Frautschy SA. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease. CNS Neurol Disord Drug Targets 9(2): 140-8 (2010).
71. 2+-channel. Brain Pathol 8(4): 641-53 (1998).
72. Veinbergs I, Everson A, Sagara Y, Masliah E. Neurotoxic effects of apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. J Neurosci Res 67(3): 379-87 (2002).
73. Qiu Z, Crutcher KA, Hyman BT, Rebeck GW. ApoE isoforms affect neuronal N-methyl-D-aspartate calcium responses and toxicity via receptor-mediated processes. Neuroscience 122(2): 291-303 (2003).
74. Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci U S A 107(26): 12011-6 (2010).
75. Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer’s disease: Accidental encounters or partners? Neuron 81(4): 740-54 (2014).
76. Kunzler J, Youmans KL, Yu C, Ladu MJ, Tai LM. APOE modulates the effect of estrogen therapy on Abeta accumulation EFAD-Tg mice. Neurosci Lett 560: 131-6 (2014).
77. Tai LM, Koster KP, Luo J, Lee SH, Wang YT, Collins NC, et al. Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem 289(44): 30538-55 (2014).
78. Jiang L, Zhong J, Dou X, Cheng C, Huang Z, Sun X. Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury. Neuroscience 301: 375-83 (2015).
79. Bour A, Grootendorst J, Vogel E, Kelche C, Dodart JC, Bales K, et al. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res 193(2): 174-82 (2008).
80. Siegel JA, Haley GE, Raber J. Apolipoprotein E isoform-dependent effects on anxiety and cognition in female TR mice. Neurobiol Aging 33(2): 345-58 (2012).
81. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075): 1503-6 (2012).
82. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease. Trends Mol Med 16(6): 287-94 (2010).